Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Susan Kopiwoda is active.

Publication


Featured researches published by Susan Kopiwoda.


International Journal of Nuclear Medicine and Biology | 1984

A comparison of the technetium-labeled myocardial agents DiArs and DMPE to 201Tl in experimental animals

Paul J. Sullivan; Jerry Werre; David R. Elmaleh; Robert D. Okada; Susan Kopiwoda; Frank P. Castronovo; Kenneth A. McKusick; H. William Strauss

The biodistribution, kinetics, imaging characteristics and blood flow correlations of 99mTc labeled DiArs and DMPE were studied. The mice biodistribution were compared to 201Tl in mice and dogs, respectively. The myocardial kinetics of these agents were evaluated in normal and ischemic myocardium using miniaturized endocardial detectors. DiArs had a lower myocardial concentration (9.4 +/- 0.8% dose/g at 1 min), than DMPE (11.7 +/- 1.1% dose/g at 1 min) but both were considerably less than 201Tl (23-26% dose/g at 1 min). The kinetic characteristic of both technetium labeled agents suggested that redistribution into ischemic myocardium would not take place, since the clearance rate from normal and ischemic myocardium was similar for both the DiArs and DMPE . The clear visualization of the canine myocardium after i.v. injection demonstrated the superiority of DMPE over DiArs and the potential use of these agents, if proven, to behave the same in human trials.


European Journal of Nuclear Medicine and Molecular Imaging | 1987

Biodistribution of tantalum-178 A short-lived radiopharmaceutical for blood pool imaging

Richard A. Wilson; Susan Kopiwoda; Ronald J. Callahan; Richard H. Moore; Charles A. Boucher; Henry Manspeaker; Frank P. Castronovo; H. William Strauss

Abstract178Ta is a short lived radionuclide (half life=9.3 min), which results in favorable radiation exposure compared to 99mTc (half life 6 h). The energy spectrum of 178Ta consists of imageable photons in the 55–65 keV (61.2%) and 93 keV (33.7%) range but also 6% of disintegrations result in photons with energies greater than 500 keV. These high energy photons cause septal penetration in low energy collimators so that resolution is degraded. However, a medium energy collimator prevents the septal penetration of these higher energy photons. Serial blood samples obtained from dog and rabbit models indicate that 178Ta is retained in the blood pool for at least 20–30 min after intravenous injection. The 178Ta appears to be associated with the protein fraction of the plasma and not primarily with the red blood cell fraction as determined by centrifugation and column chromatography. Gated equilibrium blood pool images using 178Ta were comparable in quality to images using the 99mTc labelled red blood cell technique. Therefore, 178Ta may allow comparable equilibrium gated blood pool imaging with much more favorable radiation dosimetry. Thus, serial studies over prolonged periods of observation may be obtained.


Journal of Radioanalytical and Nuclear Chemistry | 1980

Biodistribution of A14C-and99mTc-labeled N-substituted nitrosourea (CCNU) in an animal tumor model

Frank P. Castronovo; Majic S. Potsaid; Susan Kopiwoda; M. Peterson

One formulation of14C labeled and another of99mTc labeled 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) were administered i.v. to tumor (glioma) bearing rats. The radiopharmacokinetics of14C-CCNU were followed up to 24 hours post injection. On a per organ basis the blood, liver, small bowel, kidney cortex and muscle contained most of the activity. Optimum tumor to organ ratios occurred at 4–12 hours. The99mTc-CCNU biodistribution was determined at 4 hours and compared to99mTc-NaTcO4. Tumor capsule to brain (29.5) and to muscle (10.59) ratios suggest99mTc-CCNU to be a potential tumor seeking agent.


The Journal of Nuclear Medicine | 1999

Imaging of Apoptosis (Programmed Cell Death) with 99mTc Annexin V

Francis G. Blankenberg; Peter D. Katsikis; Jonathan F. Tait; R. Eric Davis; Louis Naumovski; Katsuichi Ohtsuki; Susan Kopiwoda; Michael J. Abrams; H. W. Strauss


The Journal of Nuclear Medicine | 1981

Myocardial Imaging with 9-[Te-123m] Telluraheptadecanoic Acid

David R. Elmaleh; Furn F. Knapp; Tsunehiro Yasuda; Jack L. Coffey; Susan Kopiwoda; Robert D. Okada; H. William Strauss


The Journal of Nuclear Medicine | 1997

Clinical Decision Making Based on Radionuclide Determined Ejection Fraction in Oncology Patients

Nan-Jing Peng; Ranjana H. Advani; Susan Kopiwoda; George A. Fisher; H. William Strauss


The Journal of Nuclear Medicine | 1982

Cardiac lymphoscintigraphy following closed-chest catheter injection of radiolabeled colloid into the myocardium of dogs: concise communication.

Osbakken; Susan Kopiwoda; A. Swan; Frank P. Castronovo; H.W. Strauss


Cancer Research | 1980

Formulation and Biological Distribution of Radiolabeled 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea in an Animal Tumor Model

Frank P. Castronovo; Majic S. Potsaid; Susan Kopiwoda


Archive | 1980

ASSESSMENT IN THE INTACT ANIMAL

Charles J. Homcy; H. William Strauss; Susan Kopiwoda


American Journal of Cardiology | 1982

Comparison of TC-99m DMPE to 201 thallium biodistribdtion

Paul J. Sullivan; Jerry Werre; Robert D. Okada; Susan Kopiwoda; Frank P. Castronovo; Kenneth A. McKusick; H. William Strauss

Collaboration


Dive into the Susan Kopiwoda's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

H. William Strauss

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Furn F. Knapp

Oak Ridge National Laboratory

View shared research outputs
Researchain Logo
Decentralizing Knowledge